Avastin useful adjunct for glaucoma therapy

Article

Avastin (bevacizumab) is a useful adjunct for the treatment of neovascular glaucoma, but it is too soon to say if it will have a long-term impact on glaucoma therapy.

Avastin (bevacizumab) is a useful adjunct for the treatment of neovascular glaucoma, but it is too soon to say if it will have a long-term impact on glaucoma therapy, according to Dr Stefan Scholl.

Alongside Professor Albert Augustin, Dr Scholl performed a study comprised of 25 glaucoma patients with neovascularization from diabetic retinopathy and retinal vein occlusion. Mean intraocular pressure (IOP) was 40.8 mmHg (patients receiving full topical medication). The patients received 2 mg Avastin intracamerally.

Following Avastin administration, slit lamp tests revealed some dramatic results, with regression of vessels as early as 48 hours after injection. After one week, mean IOP was 36.2mmHg, and after two weeks it was 22.8 mmHg. At three weeks it dropped to 15.9 mmHg.

"Absolutely no assumption can be made on the long-term impact of Avastin because topical medication might also be required as well as Avastin re-treatment," said Dr Scholl. "But it can be considered a useful adjunct to more stable treatments, such as photocoagulation."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.